The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses

ZoomRx Has Tweaked ChatGPT For Pharma

ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.

ChatGPT Bard
OpenAI's ChatGPT and Google's rival Bard AI are promising to automate many fields once considered beyond the reach of technology. • Source: Shutterstock

As excitement around ChatGPT and other generative AI programs grows, one company, ZoomRx, has launched its own tool to help transform how pharma analyzes data coming out of medical congresses.

More from Business

Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular

 

Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.

2024 Drug Launches Reflect A Breakout Year For Liver Disease

 

The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process

 

The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.

More from Scrip

Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process

 

The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.

Another Major DLL3 ADC Alliance As Hengrui Links With IDEAYA

 

The new year has already brought multiple deals for China-originated antibody-drug conjugates in the DLL3 class, which companies in the country dominate.

CARsgen Claims First Clinical Win For CLDN 18.2 CAR-T In G/GEJ Adenocarcinoma

 

CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.